Jörg Sievers

1.3k total citations
24 papers, 447 citations indexed

About

Jörg Sievers is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Jörg Sievers has authored 24 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 12 papers in Virology and 5 papers in Molecular Biology. Recurrent topics in Jörg Sievers's work include HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (5 papers). Jörg Sievers is often cited by papers focused on HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (5 papers). Jörg Sievers collaborates with scholars based in United Kingdom, United States and Germany. Jörg Sievers's co-authors include Jeff Errington, Michael Aboud, Mark Underwood, Marcelo Losso, Dietmar Linder, Richard Kaplan, U Müller, Eckhard Bill, Marcus Hans and Julia A. Vorholt and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Jörg Sievers

23 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jörg Sievers United Kingdom	9	194	175	120	114	69	24	447
MohamedHusen Munshi India	6	221 1.1×	216 1.2×	184 1.5×	36 0.3×	32 0.5×	7	463
Iain K. Pemberton United Kingdom	12	342 1.8×	64 0.4×	54 0.5×	171 1.5×	63 0.9×	17	465
Sally‐J. Rowland United Kingdom	9	347 1.8×	132 0.8×	25 0.2×	202 1.8×	94 1.4×	12	438
Valérie Labrousse France	8	251 1.3×	125 0.7×	35 0.3×	108 0.9×	33 0.5×	10	478
Jean–Marc Juteau United States	9	131 0.7×	81 0.5×	38 0.3×	26 0.2×	20 0.3×	14	428
Beatriz Llano-Sotelo United States	7	334 1.7×	68 0.4×	13 0.1×	78 0.7×	57 0.8×	8	473
Linda E. Chovan United States	9	109 0.6×	44 0.3×	47 0.4×	17 0.1×	20 0.3×	13	354
Christopher R. Houchens United States	10	159 0.8×	42 0.2×	24 0.2×	34 0.3×	13 0.2×	13	281
Eva Zbornı́ková Czechia	9	240 1.2×	64 0.4×	9 0.1×	99 0.9×	48 0.7×	16	373
D L Heefner United States	9	234 1.2×	104 0.6×	68 0.6×	76 0.7×	13 0.2×	10	422

Countries citing papers authored by Jörg Sievers

Since Specialization

Citations

This map shows the geographic impact of Jörg Sievers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörg Sievers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörg Sievers more than expected).

Fields of papers citing papers by Jörg Sievers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörg Sievers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörg Sievers. The network helps show where Jörg Sievers may publish in the future.

Co-authorship network of co-authors of Jörg Sievers

This figure shows the co-authorship network connecting the top 25 collaborators of Jörg Sievers. A scholar is included among the top collaborators of Jörg Sievers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörg Sievers. Jörg Sievers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Underwood, Mark, Ruolan Wang, J Oyee, et al.. (2024). Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies. Viruses. 16(3). 405–405. 2 indexed citations

Hogrefe, Katharina, Ferdinand Toberer, Felipe C. Geyer, Jörg Sievers, & Holger A. Haenssle. (2024). Bilateral hemorrhage of lower legs evolving into gangrene in a young woman with systemic symptoms. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 23(4). 532–535.

Madero, Juan Sierra, Núria Espinosa, Roberto Gulminetti, et al.. (2023). Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies. JAIDS Journal of Acquired Immune Deficiency Syndromes. 94(3). e9–e12. 3 indexed citations

Brown, Dannae, Richard Kaplan, Marcelo Losso, et al.. (2022). Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study. Antiviral Therapy. 27(2). 3 indexed citations

Ait‐Khaled, Mounir, Juan Sierra Madero, Vicente Estrada, et al.. (2021). Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies. SHILAP Revista de lepidopterología. 23(1). 9–14. 6 indexed citations

Ait‐Khaled, Mounir, Choy Man, Jörg Sievers, et al.. (2020). 1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials. Open Forum Infectious Diseases. 7(Supplement_1). S541–S542. 1 indexed citations

Aboud, Michael, Richard Kaplan, Johannes Lombaard, et al.. (2019). Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. The Lancet Infectious Diseases. 19(3). 253–264. 104 indexed citations

Aboud, Michael, Richard Kaplan, Johannes Lombaard, et al.. (2019). Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study. Journal of Infection and Public Health. 12(1). 107–107. 5 indexed citations

Ross, Lisa, et al.. (2015). Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens. The Open AIDS Journal. 9(1). 38–44. 2 indexed citations

10.

Wood, Robin, et al.. (2013). Long-Term Safety Study of Fosamprenavir-Containing Regimens in HIV-1–Infected Patients. HIV Clinical Trials. 14(5). 183–191. 2 indexed citations

11.

Fortuny, Clàudia, Dan Duiculescu, H Garges, et al.. (2013). Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children. The Pediatric Infectious Disease Journal. 33(1). 50–56. 8 indexed citations

12.

Cotton, Mark F., Noris Pavía-Ruz, H Garges, et al.. (2013). Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data. The Pediatric Infectious Disease Journal. 33(1). 57–62. 6 indexed citations

13.

Şener, Burçin, Sercan Ulusoy, Alper Tünger, et al.. (2007). A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004–2005. Journal of Antimicrobial Chemotherapy. 60(3). 587–593. 36 indexed citations

14.

Stokes, Neil R., Jörg Sievers, Stephanie Barker, et al.. (2005). Novel Inhibitors of Bacterial Cytokinesis Identified by a Cell-based Antibiotic Screening Assay. Journal of Biological Chemistry. 280(48). 39709–39715. 96 indexed citations

15.

Sievers, Jörg, et al.. (2002). Characterization of the parB -Like yyaA Gene of Bacillus subtilis. Journal of Bacteriology. 184(4). 1102–1111. 20 indexed citations

16.

Sievers, Jörg & Jeff Errington. (2000). The Bacillus subtilis cell division protein FtsL localizes to sites of septation and interacts with DivIC. Molecular Microbiology. 36(4). 846–855. 41 indexed citations

17.

Sievers, Jörg & Jeff Errington. (2000). Analysis of the Essential Cell Division GeneftsLofBacillus subtilisby Mutagenesis and Heterologous Complementation. Journal of Bacteriology. 182(19). 5572–5579. 17 indexed citations

18.

Hans, Marcus, Jörg Sievers, U Müller, et al.. (1999). 2‐Hydroxyglutaryl‐CoA dehydratase from Clostridium symbiosum. European Journal of Biochemistry. 265(1). 404–414. 48 indexed citations

19.

Schrenck, T. von, et al.. (1994). Signal transduction pathway of the muscarinic receptors mediating gallbladder contraction. Naunyn-Schmiedeberg s Archives of Pharmacology. 349(4). 346–354. 8 indexed citations

20.

Schrenck, T. von, et al.. (1993). Characterization of muscarinic receptors on guinea pig gallbladder smooth muscle. Gastroenterology. 105(5). 1341–1349. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact